Janssen announces the latest data from two gene therapy programs

Janssen Pharmaceutical Companies of Johnson & Johnson announces preliminary results from a Phase 1/2 study evaluating investigative gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with hereditary retinitis pigmentosa (XLRP)-associated retinitis. pigmentary; The retinitis pigmentosa regulator gene GTPase (RPGR). The announcement was made Friday during late oral presentations on Retina Subspecialty Day at the American … Read more